Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?


Ulas A., Avci N., Kos T., Cubukcu E., Olmez O. F. , Bulut N., ...More

Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, pp.714-22, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20
  • Publication Date: 2015
  • Journal Name: Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.714-22
  • Keywords: breast cancer, HER2 positive, lymphocytes, neutrophil, platelet, TUMOR-INFILTRATING LYMPHOCYTES, EPITHELIAL OVARIAN-CANCER, CELL LUNG-CANCER, NEUTROPHIL/LYMPHOCYTE RATIO, PRETREATMENT NEUTROPHIL, GROWTH-FACTOR, COLORECTAL-CANCER, PERIPHERAL-BLOOD, GASTRIC-CANCER, JOINT ANALYSIS
  • Bursa Uludag University Affiliated: Yes

Abstract

Purpose: To investigate whether the pretreatment neutrophil lymphocyte ratio (NLR) and the platelet lymphocyte ratio (PLR) have any prognostic significance in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab.